基本信息 产品详情 公司简介 推荐产品
网站主页 化工产品目录 原料药 抗肿瘤药 奥卡妥珠单抗
  • (Ocaratuzumab)Biosimilar Reference Antibody-GS40486
  • (Ocaratuzumab)Biosimilar Reference Antibody-GS40486

1/2

(Ocaratuzumab)Biosimilar Reference Antibody-GS40486 新品

Ocaratuzumab
300 100μg 起订
湖北 更新日期:2026-03-12

武汉迈思生物科技有限公司

VIP1年
联系人:市场
电话:027-65523427拨打
手机:18007167883 拨打
邮箱:Service@mabnus.com

产品详情:

英文名称:
Ocaratuzumab
CAS号:
1169956-08-4
品牌:
Mabnus
产地:
武汉
保存条件:
store at -20°C or -80°C. Avoid repeated freeze.
纯度规格:
>95% by SDS-PAGE
重组:
应用:
ELISA;FC;Functional Assays;IF
种属反应性:
Human
宿主:
Humanised
偶联物:
靶点:
MS4A1/CD20
免疫原:
MS4A1/CD20
亚型:
IgG1 - kappa
验证方法:
ELISA plate pre-coated Antigen protein, can bind Ocaratuzumab biosimilar in a linear range of 3.91–31 ng/mL.

货号:GS40486

Ocaratuzumab (also known as AME‑133v or LY2469298) is a humanized, Fc‑engineered monoclonal antibody that targets CD20, a B‑cell surface antigen. Its Fc region is engineered (with enhanced affinity for FcγRIIIa) to potentiate antibody‑dependent cellular cytotoxicity (ADCC) against CD20‑positive B cells. Compared to the first‑generation anti‑CD20 antibody rituximab, ocaratuzumab is designed to provide stronger ADCC, particularly in patients carrying the lower‑affinity FcγRIIIa‑158F polymorphism. It was developed as a potential therapy for B‑cell non‑Hodgkin lymphoma (NHL) and was evaluated in clinical trials for relapsed/refractory follicular lymphoma, but its development has been discontinued.


Ocaratuzumab;

公司简介

武汉迈思生物科技有限公司立足于解决行业内功能活性蛋白表达及高亲和力、高灵敏度抗体开发难的痛点,依托自建的两大核心技术平台:哺乳动物细胞蛋白表达平台和单个B细胞抗体开发平台,竭诚为广大科研机构、高等院校、IVD企业、医药企业等提供一站式蛋白表达及抗体开发相关产品和技术服务。

成立日期 (5年)
注册资本 壹佰伍拾万圆人民币
员工人数 10-50人
年营业额 ¥ 1000万-5000万
经营模式 工厂,试剂,定制,服务
主营行业 抗体,蛋白组学

Ocaratuzumab相关厂家报价

内容声明
拨打电话 立即询价